The Boston biotech IPO train may be starting up again. After a couple of slow months, obesity drugmaker Zafgen has brought in $96 million in its Nasdaq debut and saw its stock price rise more than 20 percent. And Syndax Pharmaceuticals has been preparing to go public this week; the Waltham company is working on an experimental drug for breast cancer. Meanwhile, Cambridge-based Sage Therapeutics has filed its paperwork for an IPO down the road. Sage is working on a number of new drug candidates that target neurological disorders. So, that’s three interesting companies to watch this summer.
In other innovation news:
— Local venture-capital firms are on the move. Boston’s Polaris Partners is raising $400 million in a new fund, according to a report in Fortune. And Bain Capital Partners has reportedly raised at least double that across two funds.
— Our startup of the week is Navitor Pharmaceuticals. The Cambridge startup has raised $23.5 million from Boston VCs and big pharma companies, to tackle autoimmune and metabolic disorders.
— And lastly, will 2015 be the year of wireless power? MIT spinout WiTricity thinks so, and it’s targeting consumer electronics, cars, and healthcare . The idea of charging batteries wirelessly has been around for a while, but new CEO Alex Gruzen thinks partnerships with Intel and automotive companies give his startup a leg up in what could become a very interesting market.
